What is NuvOx Pharma?
NuvOx Pharma, headquartered in Tucson, Arizona, is a clinical-stage biotechnology company dedicated to developing novel oxygen therapeutics for life-threatening diseases linked to hypoxia. The company's flagship product, NanO₂, is currently progressing through clinical trials for indications such as glioblastoma and stroke. NuvOx Pharma's commitment to enhancing oxygen flow and patient safety positions it as a key player in advancing treatments for critical medical conditions.
How much funding has NuvOx Pharma raised?
NuvOx Pharma has raised a total of $1.1M across 2 funding rounds:
Grant
$1M
Debt
$150K
Grant (2014): $1M with participation from National Cancer Institute
Debt (2020): $150K led by PPP
Key Investors in NuvOx Pharma
National Cancer Institute
The National Cancer Institute is a leading U.S. government agency focused on cancer research, aiming to reduce cancer prevalence and improve patient outcomes through scientific investigation and the development of new interventions.
PPP
Public-Private Partnership
What's next for NuvOx Pharma?
The recent major strategic investment provides NuvOx Pharma with significant resources to advance its NanO₂ therapeutic through its clinical trial phases. This backing is expected to accelerate research and development efforts, potentially leading to pivotal breakthroughs in treating hypoxia-related conditions. The company's focus on addressing unmet medical needs in oncology and neurology suggests a strategic expansion of its therapeutic pipeline and market reach.
See full NuvOx Pharma company page
